Technology
Health
Medical
Soleno Therapeutics
$1.959876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$1.95
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$0.08 (-3.94%) Today
$0.00 (0.00%) After Hours
Why Robinhood?
You can buy or sell SLNO and other stocks, options, ETFs, and crypto commission-free!
About
Soleno Therapeutics, Inc. engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. It markets CoSense End-Tidal Carbon Monoxide monitor, which measures ETCO and is used by hospitals to detect hemolysis in newborns. Read More The company was founded on August 25, 1999 and is headquartered in Redwood City, CA.
Employees
23
Headquarters
Redwood City, California
Founded
1999
Market Cap
61.96M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
472.03K
High Today
$2.07
Low Today
$1.91
Open Price
$2.07
Volume
19.64K
52 Week High
$5.07
52 Week Low
$1.11
Collections
Technology
Health
Medical
Therapy
2014 IPO
US
North America
News
Yahoo FinanceMay 13
Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2019 Financial Results
REDWOOD CITY, Calif., May 13, 2019 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the three months ended March 31, 2019. “Enrollment in our Phase III DESTINY PWS trial evaluating Diazoxide Choline Controlled-Release (DCCR) tablets for the treatment of Prader-Willi Syndrome (PWS) continues to progress,” said Ani...
Price Paid on Robinhood
38% Lower
Right Now
52 Week Low
$1.11
Average Price Paid
$3.14
52 Week High
$5.07
Earnings
-$0.36
-$0.23
-$0.11
$0.02
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
-$0.29 per share
Actual
-$0.22 per share